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cines can successfully prevent infection by common
pathogens (such as flu, hepatitis, HIV, and malaria)
The threat posed by bioterrorism has been recognized (Ulmer et al., 1993; Sedegah et al., 1994; Wang et al.,
1995; Boyer et al., 1997; Davis and Brazolot Millan, 1997).by the military, articulated by the President, and de-
Several phase I clinical trials have examined the safetyscribed in articles published in leading newspapers and
of DNA plasmids in humans. Findings indicate that thesescholarly journals (Henderson, 1999). We've learned that
agents can be administered at high doses to normalforeign governments developed biological agents (in-
recipients without serious side effects (Calarota et al.,cluding anthrax, smallpox, and plague) for use as weap-
1998; Wang et al., 1998). Such studies also provide infor-ons of mass destruction, and that the technology to
mation on the immunogenicity of DNA vaccines in hu-create these agents was transferred to nations with in-
mans (Calarota et al., 1998; Wang et al., 1998). Withoutterests inimical to those of the United States (Altas,
exception, the dose of vaccine required to elicit a detect-1998; Henderson, 1999; Seelos, 1999). The low cost and
able immune responses in humans was considerablyrelative ease with which biowarfare agents can be
higher than that expected on the basis of animal studies.prepared led to their acquisition by radical/dissident
Moreover, the magnitude of the human antibody (Ab)groups. For example, the Japanese Aum Shinrikyo cult
and cytotoxic T lymphoctye (CTL) response was consid-prepared and reportedly exposed Japanese civilians to
erably lower than that observed in mice (Calarota et al.,anthrax and botulinum toxin. Researchers endeavoring
1998; Wang et al., 1998).to counter such threats are developing novel and effec-
The difference in immunogenicity of DNA vaccines intive antimicrobial drugs, pathogen-specific vaccines,
mice versus humans has not been explained. It is possi-and immunostimulatory agents capable of boosting the
ble that the plasmid vectors used to construct DNAhost's resistance to infectious agents. An important
vaccines contain motifs that are immunosuppressive incomponent of these efforts involves the use of foreign
humans (Krieg et al., 1998b). Alternatively, physiologicDNA to improve innate and adaptive immunity to bio-
differences in muscle mass, uptake, or processing ofwarfare pathogens.
plasmid DNA by antigen-presenting cells, or plasmidThe immune system evolved two general mechanisms
half-life in vivo may explain differences in vaccine immu-for combating infectious diseases. The initial or ªinnateº
nogenicity between species. Multiple strategies to im-immune response is triggered within minutes of infection
prove the activity of DNA vaccines in primates are beingand serves to limit the pathogen's spread in vivo. Host
pursued, including plans to ªhumanizeº the antigen-recognition of conserved determinants expressed by a
encoding gene, coadminister plasmids encoding cytokinediverse range of infectious microorganisms but absent
and/or costimulatory molecules, improve promoter re-from the host (such as LPS) stimulate elements of the
gion function, delete suppressive sequences, and/or im-innate immune system to produce immunomodulatory
prove cellular uptake of the plasmid (Hengge et al., 1995;cytokines and polyreactive IgM antibodies (reviewed in
Xiang and Ertl, 1995; Hartikka et al., 1996; Iwasaki et al.,Marrack and Kappler, 1994; Medzhitov and Janeway,
1997; Okada et al., 1997; Cohen et al., 1998; Kim et al.,1997, 1998). Subsequently, an ªadaptiveº or antigen-
1998; Krieg et al., 1998b; Weiss et al., 1998).specific immune response is generated against determi-
The use of DNA plasmids offers several importantnants expressed uniquely by the pathogen. Efforts are
advantages over conventional vaccine strategies for de-underway to use DNA-based technology, including DNA
veloping antibiowarfare agents. DNA vaccines can be
vaccines and immunostimulatory synthetic oligodeoxy-
prepared from minute amounts of DNA isolated from a
nucleotides (ODN), to induce both innate and adaptive
pathogen, eliminating the need to culture or attenuate
immune responses against biothreat agents. large stocks of deadly bacteria or viruses. For this pur-
pose, the genes that encode immunogenic proteins can
DNA Vaccines to Counter Bioterrorism be rapidly cloned into pretested vectors and used for
The ability of antigen-encoding DNA plasmids to induce vaccine production. Even if the immunogenic genes/
cellular and humoral immune responses against patho- proteins from a given pathogen are unknown, the entire
genic viruses, bacteria, and toxins is revolutionizing vac- genome can be ªshotgunº cloned into such vectors and
cine development (Figure 1). DNA vaccines are com- then screened for activity (Johnston and Barry, 1997).
posed of an antigen-encoding gene whose expression Using these approaches, scientists have developed
is regulated by a strong mammalian promoter expressed first-generation DNA vaccines against biothreat agents.
on a plasmid backbone of bacterial DNA (Ulmer et al., These include vaccines targeting cell surface, envelope,
and/or nucleoproteins expressed by bacterial and viral
pathogens (such as Ebola and Yersinia [Vanderzanden* To whom correspondence should be addressed (e-mail: klinman@
CBER.FDA.GOV). et al., 1998; Xu et al., 1998; Noll et al., 1999]), and the
Immunity
124
Figure 1. Mechanisms of Protection
CpG ODN stimulate the cellular and humoral effector arms of the innate immune system to reduce pathogen load, while DNA vaccines
induce long-lasting antigen-specific immunity. The effect of the CpG ODN can be direct (solid arrows) or, by inducing the activation of an
immunomodulatory cascade, indirect (dashed arrows).
toxins they secrete (such as the PA component of the al., 1996; Sun et al., 1997). In vivo and in vitro studies
conducted in mice demonstrate that a hexameric motifanthrax toxin [Gu et al., 1999]) (Figure 1).
consisting of a central unmethylated CpG dinucleotide
flanked by two 59 purines and two 39 pyrimidines triggerCpG ODN as Immunoprotective Agents
While considerable effort is being directed toward de- such immune activation (Yamamoto et al., 1992; Halpern
et al., 1996; Klinman et al., 1996; Liang et al., 1996;veloping vaccines that can protect against biothreat
agents, such efforts cannot entirely eliminate the threat Roman et al., 1997). Due to a combination of CpG sup-
pression and CpG methylation, unmethylated CpG hex-posed by bioterrorism. First, it can take more than a
decade to produce, test, and license a new vaccine, amers are 20-fold more common in prokaryotic than
mammalian DNA (reviewed in Razin and Friedman, 1981;whereas mutant pathogens capable of circumventing
the immune response elicited by such vaccines can be Bird, 1987).
CpG ODN enter lymphocytes and antigen-presentinggenerated in a matter of months. Second, it may not be
possible to develop vaccines that are effective against cells within seconds, upregulate mRNA within minutes,
and stimulate the release of immunoprotective cyto-all biowarfare agents. Third, the public may refuse immu-
nization, especially if certain vaccines are found to be kines and polyreactive IgM Abs within hours of adminis-
tration (Figure 1) (Yamamoto et al., 1992; Klinman et al.,reactogenic. In this context, even members of the armed
forces have expressed concern about the side effects 1996; Stacey et al., 1996; Yi et al., 1996a; Jakob et al.,
1998; Sparwasser et al., 1998; Weeratna et al., 1998;of currently available vaccines. Finally, vaccines that are
safe and effective in healthy adults may leave newborns, Davis, 1999; Noll et al., 1999; Sparwasser and Lipford,
1999). This triggers an immunomodulatory cascade thatthe elderly, and the immunocompromised at risk of in-
fection (Effros and Walford, 1983; Paganelli et al., 1994). culminates in the recruitment of other immunologically
relevant cells, such as T lymphocytes (Chu et al., 1997;Given these concerns, additional strategies for reducing
the threat posed by bioterrorism are being pursued. For Sun et al., 1998). The molecular mechanisms underlying
CpG ODN-induced immune activation are being eluci-example, the rapid delivery of effective antibiotics may
limit the proliferation and spread of certain pathogens dated. ODN enter host cells through endocytic vesicles.
These become acidified, leading to the generation of(Seelos, 1999). Yet biowarfare agents can be genetically
manipulated to resist such therapy, as shown by the reactive oxygen species and the activation of NF-kB (Yi
et al., 1998). Translocation of NF-kB from the cytoplasmdevelopment of antibiotic-resistant strains of anthrax
(Henderson, 1999; Seelos, 1999). to the nucleus increases the transcriptional activity of
the promoter regions of IL-6, IL-12, and TNFa (Krieg etAn alternative strategy is to use immunomodulatory
agents to broadly stimulate the innate immune system, al., 1995; Yi et al., 1996a). CpG ODN also induce stress
kinase activity (JNK1/2, p38), resulting in the activationthereby improving host resistance against infectious
agents (Hadden, 1993). Recent reports demonstrate that of AP-1 (Hacker et al., 1998; Yi and Krieg, 1998).
Immune recognition of CpG motifs has been evolu-foreign DNA (from bacteria, parasites, yeast, and in-
sects) may induce a protective innate immune response tionarily conserved in species ranging from mice to hu-
mans (Ballas et al., 1996; Klinman et al., 1996; Davis,(Yamamoto et al., 1992; Krieg et al., 1995; Klinman et
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Figure 2. Strategies for the Use of DNA Vac-
cines and/or CpG ODN to Counter the Threat
Posed by Biowarfare Agents
(A) DNA vaccines (blue) induce a protective
antigen-specific immune response prior to
pathogen exposure (red).
(B) Unfortunately, this response develops too
slowly to prevent pathology if vaccination is
delayed until after infection (cross).
(C and D) CpG ODN (green) stimulate a rapid
protective innate immune response if admin-
istered prior to and, in some cases, after
pathogen exposure. The outcome of such
treatment can either result in survival or death
(dashed red lines).
(E and F) Optimally, CpG ODN administered
in combination with DNA vaccine induce a
rapidly protective innate immune response
that synergistically boosts Ag-specific immu-
nity. The x axis represents time, while the y
axis represents the magnitude of infection or
the immune response.
1999; Wagner, 1999). This led us to postulate that the Phosphorothioate-modified ODN (pODN) are com-
monly used for CpG studies. The phosphorothioateresultant immune response contributed to host survival
(Krieg et al., 1995; Klinman, 1998). It was recently shown backbone reduces the susceptibility of the ODN to
DNAse digestion, significantly prolonging half-life inthat 10±50 mg of CpG ODN administered intramuscu-
larly, intraperitoneally, intravenously, or intradermally vivo. pODN are readily manufactured in pure form, are
stable at room temperature, and are easily reconstitutedcompletely protected mice from 102±103 LD50 of Ebola,
anthrax, and listeria, and up to 105 LD50 of tularemia for rapid administration. They are also intrinsically immu-
nostimulatory, which further boosts the cytokine and(Klinman, 1998; Krieg et al., 1998a; Zimmermann et al.,
1998; Elkins et al., 1999), all potential biothreat agents. IgM production elicited by the CpG motifs they express
(Stein and Cheng, 1993; Hartmann et al., 1996; Liang etCpG ODN also confer protection against a variety of
parasitic diseases that could reduce military prepared- al., 1996; Monteith et al., 1997). Of interest, the se-
quences that are optimally stimulatory in mice are poorlyness, such as malaria, leishmania, and schistosomiasis
(Sparwasser et al., 1997a; Krieg et al., 1998a; Elkins et active on cells from primates, and vice versa (Liang et
al., 1996; Davis, 1999; Wagner, 1999). This suggestsal., 1999). The innate immune response elicited by CpG
ODN limits a pathogen's early proliferation. This allows that the fine specificity of the DNA-binding protein(s)
involved in CpG recognition have diverged between spe-the host to develop a sterilizing pathogen-specific im-
mune response and provides a window of opportunity cies and helps explain the comparatively poor immuno-
genicity of DNA vaccines in humans. Unfortunately,for medical personnel to initiate additional life-saving
interventions (Krieg et al., 1998a; Elkins et al., 1999) pODN are toxic at high doses and can cause undesirable
immune activation (Davis, 1999; Monteith et al., 1999;(Figure 1). Thus, mice treated with CpG ODN prior to
pathogen challenge not only survived immediate infec- Wagner, 1999). Thus, ongoing efforts are directed to-
ward developing novel forms of nuclease-resistant ODNtion but developed long-lasting pathogen-specific im-
munity (Elkins et al., 1999). In this context, combining and identifying the length, flanking sequence, and num-
ber of CpG motifs required to maximize the immuneCpG ODN with immune modulators such as DNA vac-
cines may afford even greater protection by increasing response in humans.
host resistance to infection while promoting the devel-
opment of an antigen-specific adaptive response (Fig- CpG DNA as Vaccine Adjuvants
CpG motifs are being examined for their ability to im-ures 2C and 2E).
Several characteristics of CpG ODN increase their prove the immunogenicity of DNA vaccines. Most inves-
tigators find that engineering additional CpG motifs intoutility as anti-bioterrorist agents. First, a single dose
provides protection for approximately 2 weeks, allowing the vector backbone of a DNA vaccine improves the
resultant antigen-specific Ab, CTL, and cytokine re-the ODN to be administered to ªat riskº populations
(e.g., medical and military personnel) prior to pathogen sponse elicited in mice (Sato et al., 1996; Klinman et al.,
1997, 1999). Improved immunogenicity is not universallyexposure (Elkins et al., 1999). Repeated doses can ex-
tend the duration of protection for many months (Figures observed, however, perhaps because certain vector/
insert combinations are so immunogenic that additional2B and 2D). Second, CpG ODN are effective against a
wide range of pathogens and thus may be of use before CpGs have no further effect (Liu et al., 1998). It has
also been shown that free CpG ODN can increase thethe causative agent has been identified. Third, CpG ODN
improve the innate immune response of individuals response to a coadministered DNA vaccine (Klinman et
al., 1999). Due to competition between ODN and plasmidwhose adaptive immune response is impaired (such as
newborns and the elderly) and thus can provide broad, vaccine for cellular uptake (Weeratna et al., 1998), these
two forms of DNA may need to be administered to differ-population-based protection from infection (Brazolot
Millan et al., 1998; Kovarik et al., 1999). ent sites.
Immunity
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CpG ODN can also boost the immune response elic- In contrast, integration is not a major concern for CpG
ited by conventional vaccines. Proof-of-concept studies ODN, which are short ssDNA fragments that lack pro-
demonstrate that CpG ODN coadministered with protein moters. However, several experiments raise concern
antigens (such as ovalbumin or b-galactosidase) stimu- that the cytokine production mediated by CpG motifs
late a 4- to 10-fold increase in antigen-specific antibody may directly harm the host. For example, CpG ODN-
and IFNg production in vivo (Chu et al., 1997; Lipford et driven TNFa production by macrophages can mediate
al., 1997; Roman et al., 1997; Klinman et al., 1999). CpG toxic shock in D-galactosamine-sensitized mice (Spar-
ODN also improve the host's response to pathogen- wasser et al., 1997b), while CpG ODN-induced IFNg can
specific epitopes. For example, when these ODN are sensitize mice to develop a Shwartzman-like reaction
coadministered with vaccines against influenza, mea- if subsequently challenged with LPS (Cowdery et al.,
sles, hepatitis B surface Ag, or tetanus toxoid, antigen- 1996).
specific Ab titers increase by up to 3 orders of magni- There is also concern that DNA vaccines or CpG ODN
tude, and the production of IFNg and antigen-specific might predispose the host to develop autoimmune dis-
CTL rises significantly (Branda et al., 1996; Brazolot Mil- ease. It is well established that CpG motifs in bacterial
lan et al., 1998; Davis et al., 1998; McCluskie and Davis, DNA can (1) stimulate the production of anti-DNA auto-
1998; Moldoveanu et al., 1998; Kovarik et al., 1999). antibodies, (2) induce the production of proinflammatory
The utility of CpG motifs is underscored by their ability cytokines, and (3) block the apoptotic death of activated
to enhance mucosal as well as systemic immunity. This lymphocytes, all of which can accelerate the develop-
is of considerable importance, since most biothreat ment of autoimmune disease (Steinberg et al., 1990;
agents gain access to the host through the respiratory Gilkeson et al., 1993, 1995; Krieg, 1995; Klinman et al.,
tract or other mucosal sites. Several studies have shown 1996; Yi et al., 1996b; Mor et al., 1997). Despite such
that coadministering CpG ODN with vaccines signifi- concerns, several groups have shown that the repeated
cantly increases antigen-specific IgA levels at mucosal administration of CpG ODN or DNA vaccine plasmids
sites (including the respiratory, GI, and reproductive does not induce sufficient immune stimulation to trigger
tracts) and IgG levels systemically (Horner et al., 1998; systemic autoimmunity in normal mice or accelerate
McCluskie and Davis, 1998; Moldoveanu et al., 1998). disease in lupus-prone animals (Katsumi et al., 1994;
An additional benefit of CpG ODN is their ability to boost Xiang et al., 1995; Mor et al., 1997; Gilkeson et al., 1998).
immunity in groups with reduced immune function, such The situation is somewhat more complex for organ-
as newborns, the elderly, and the immunosuppressed. specific autoimmune diseases, which are promoted by
For example, recent studies indicate that CpG ODN ad- the strong Th1 responses induced by CpG ODN. In an
ministered to young animals can boost serum Ab levels IL-12-dependent model of experimental allergic en-
and/or improve Th1 responses to coadministered vac- cephalomyelitis (EAE), animals treated with CpG motifs
cines (Brazolot Millan et al., 1998; Kovarik et al., 1999). and challenged with myelin basic protein generated
By activating professional antigen-presenting cells and autoreactive Th1 effector cells, triggering the develop-
stimulating the production of Th1 and proinflammatory ment of EAE (Segal et al., 1997). In a molecular mimicry
cytokines, CpG ODN apparently create an immune mi- model, CpG motifs acted as potent immune activators,
lieu that facilitates the induction of antigen-specific im- inducing autoimmune myocarditis when coinjected with
munity. chlamydia-derived antigens (Bachmaier et al., 1999).
These findings indicate that CpG motifs may trigger del-
Safety of Foreign DNA eterious autoimmune reactions under certain circum-
The risks of using CpG ODN or DNA vaccines to stimu- stances. There is also evidence that CpG ODN can alter
late innate or adaptive immunity must be considered. the cytokine milieu (ratio of Th1 to Th2 secreting cells)
These include the possibility of their (1) integrating into of the host and synergistically enhance the toxicity of
the host genome, increasing the risk of malignancy (by
other immunostimulatory agents (Cowdery et al., 1996;
activating oncogenes or inactivating tumor suppressor
Sparwasser et al., 1997a).
genes), (2) inducing autoimmune disease (by triggering
Balancing these safety concerns, toxicity has notthe recognition of transfected cells and/or the produc-
been observed in normal animals injected with therapeu-tion of anti-DNA autoantibodies), (3) altering immune
tic doses of DNA vaccine or CpG ODN. In addition, nonehomeostasis (by skewing the balance between Th1, Th2,
of the human volunteers exposed to DNA vaccines orand proinflammatory cytokines), or (4) having direct
anti-sense ODN have suffered serious adverse conse-toxic effects on the host.
quences.Several groups have examined the persistence of DNA
vaccines in vivo. Despite differences between vector/
Conclusioninsert combinations, most plasmid remains localized to
The capacity of foreign DNA, in the form of DNA vaccinesthe site of injection and persists for weeks to months
and CpG ODN, to stimulate the mammalian immune(Ishii et al., 1999; Martin et al., 1999). Low levels of plas-
system has only recently been appreciated. Yet multiplemid migrate to other sites in the body, perhaps carried
phase I clinical trials involving these products are under-by transfected white blood cells (Martin et al., 1999).
way or planned. This rapid transition from the lab to theWhile there is no definitive evidence that plasmids inte-
clinic was facilitated by advances in molecular biologygrate into somatic or germline cells, the vector does
that accelerated the preparation of pathogen-specificbecome ªassociatedº with high±molecular weight (ge-
DNA vaccines and immunomodulatory ODN. In vitro andnomic) DNA (Martin et al., 1999). Since DNA vaccines
in vivo analysis of rodents, primates, and other animalscarry strong promoters, integration could have a pro-
found impact on the host. indicate that unmethylated CpG motifs reproducibly
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Davis, H.L., and Brazolot Millan, C.L. (1997). DNA-based immuniza-stimulate an innate immune response characterized by
tion against hepatitis B virus. Springer Semin. Immunopathol. 19,the production of IL-18 and TNFa (which improve anti-
195±209.gen-presenting cell function), IL-6 (which facilitates B
Davis, H.L., Weeranta, R., Waldschmidt, T.J., Tygrett, L., Schorr, J.,cell responses), and IFNg and IL-12 (which support the
and Krieg, A.M. (1998). CpG DNA is a potent enhancer of specific
development of Th1-dependent immune responses and immunity in mice immunized with recombinant hepatitis B surface
the generation of CTL) (Figure 1). antigen. J. Immunol. 160, 870±876.
We believe that combining the immunomodulatory Effros, R.B., and Walford, R.L. (1983). Diminished T cell response
properties of CpG ODN with the antigen-specific re- to influenza virus in aged mice. Immunology 49, 387±393.
sponses induced by DNA vaccines will substantially re- Elkins, K.L., Rhinehart-Jones, T.R., Stibitz, S., Conover, J.S., and
Klinman, D.M. (1999). Bacterial DNA protects mice against lethalduce the threat from bioterrorism. CpG ODN have been
infection by intracellular bacteria. J. Immunol. 162, 2991±2997.shown to enhance host resistance to a variety of infec-
Gilkeson, G.S., Riuz, P., Howell, D., Lefkowith, J.B., and Pisetsky,tious microorganisms and accelerate the development
D.S. (1993). Induction of immune-mediated glomerulonephritis inof long-lived pathogen-specific immunity (Figure 2).
normal mice immunized with bacterial DNA. Clin. Immunol. Immuno-
DNA vaccines are being developed against all identified pathol. 68, 283±292.
biothreat agents and have the potential to induce pro- Gilkeson, G.S., Pippen, A.M., and Pisetsky, D.S. (1995). Induction
tective antibody and CTL responses. As technology im- of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/
proves and the motifs that are optimally active in humans NZW mice by immunization with bacterial DNA. J. Clin. Invest. 95,
1398±1402.are identified, this strategy should contribute to both
Gilkeson, G.S., Conover, J.S., Halpern, M., Pisetsky, D.S., Feagin,short-term and persistent protection from the threat of
A., and Klinman, D.M. (1998). Effects of bacterial DNA on cytokinebioterrorism.
production by (NZB/NZW)F1 mice. J. Immunol. 161, 3890±3895.
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